CYTO: חוב לטווח קצר של החברה Altamira Therapeutics Ltd

Altamira Therapeutics (CYTO) is developing inhalation agents to combat pulmonary pathologies and allergies using flexible substance transport methods. The market valuation trend for the asset based on the separate_debt_short metric is 0.00. The business's profitability is based on patent protection for nasal sprays used in RNA therapy. Currently, Altamira Therapeutics is focusing on licensing its developments to industry behemoths, moving away from mergers and heavy assets.

Altamira Therapeutics' development in the RNA delivery segment requires precise liquidity management to sustain clinical trials. An analysis of financial debts with a maturity of up to one year, aggregating all short-term liabilities, allows for an assessment of the company's solvency and refinancing risk; minimal values for this indicator confirm balance sheet stability but may suggest a conservative approach to scaling the business.